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BACKGROUND
We observed an apparent increase in the rate of device thrombosis among patients 
who received the HeartMate II left ventricular assist device, as compared with preap-
proval clinical-trial results and initial experience. We investigated the occurrence of 
pump thrombosis and elevated lactate dehydrogenase (LDH) levels, LDH levels presag-
ing thrombosis (and associated hemolysis), and outcomes of different management 
strategies in a multi-institutional study.
METHODS
We obtained data from 837 patients at three institutions, where 895 devices were 
implanted from 2004 through mid-2013; the mean (±SD) age of the patients was 55±14 
years. The primary end point was confirmed pump thrombosis. Secondary end points 
were confirmed and suspected thrombosis, longitudinal LDH levels, and outcomes 
after pump thrombosis.
RESULTS
A total of 72 pump thromboses were confirmed in 66 patients; an additional 36 throm-
boses in unique devices were suspected. Starting in approximately March 2011, the occur-
rence of confirmed pump thrombosis at 3 months after implantation increased from 
2.2% (95% confidence interval [CI], 1.5 to 3.4) to 8.4% (95% CI, 5.0 to 13.9) by Janu-
ary 1, 2013. Before March 1, 2011, the median time from implantation to thrombosis was 
18.6 months (95% CI, 0.5 to 52.7), and from March 2011 onward, it was 2.7 months 
(95% CI, 0.0 to 18.6). The occurrence of elevated LDH levels within 3 months after im-
plantation mirrored that of thrombosis. Thrombosis was presaged by LDH levels that 
more than doubled, from 540 IU per liter to 1490 IU per liter, within the weeks before 
diagnosis. Thrombosis was managed by heart transplantation in 11 patients (1 patient 
died 31 days after transplantation) and by pump replacement in 21, with mortality equiv-
alent to that among patients without thrombosis; among 40 thromboses in 40 patients 
who did not undergo transplantation or pump replacement, actuarial mortality was 
48.2% (95% CI, 31.6 to 65.2) in the ensuing 6 months after pump thrombosis.
CONCLUSIONS
The rate of pump thrombosis related to the use of the HeartMate II has been increas-
ing at our centers and is associated with substantial morbidity and mortality.
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The HeartMate II (Thoratec), a small, axial-flow left ventricular assist device (LVAD), rapidly became integral to 
the treatment of patients with advanced heart 
failure.1 Pivotal trials and postmarketing approval 
studies of the HeartMate II provide a reference 
occurrence of thrombosis of 2 to 4%2-4; however, 
an unexpected abrupt increase in the incidence 
of pump thrombosis was observed in a single-
center quality review. To confirm that this find-
ing was not an isolated phenomenon, two addi-
tional experienced centers pooled data to investigate 
the incidence of pump thrombosis and of elevat-
ed lactate dehydrogenase (LDH) levels as its clini-
cal biomarker (indicating hemolysis), LDH levels 
that may presage thrombosis, and outcomes of 
thrombosis-management strategies.
Me thods
Patients
A total of 895 HeartMate II LVADs were implant-
ed in 837 patients at three institutions: Cleveland 
Clinic from October 2004 through February 2013 
(296 devices in 280 patients), Washington Univer-
sity Barnes–Jewish Hospital from January 2004 
through April 2013 (307 devices in 287 patients), 
and Duke University Medical Center from May 
2005 through May 2013 (292 devices in 270 pa-
tients). At the three respective institutions, the mean 
(±SD) ages of the patients were 54±14, 54±13, and 
58±14 years, with an overall average of 55±14 years; 
19.3%, 16.4%, and 27.8% of the patients were 
women, with an overall average of 21.0%.
Study Data
Limited, partially deidentified data were provided 
for analysis under data-use agreements and with 
approval from the institutional review board at 
each institution to use these data in research; the 
requirement to obtain informed consent from the 
patients was waived. Variables in common across 
the three institutions included the date of Heart-
Mate II implantation, the number of HeartMate II 
devices each patient had previously received, age 
at each HeartMate II implantation, sex, bridge-to-
transplantation versus destination therapy as the 
indication for mechanical circulatory support, and 
surgeon. The medical records of patients with 
confirmed or suspected pump thrombosis were 
scrutinized by investigators at each site to verify 
diagnostic evidence.
The electronic medical-records systems at the 
hospitals were queried to extract serial values of 
LDH during HeartMate II support. We obtained 
12,379 LDH measurements for 568 devices (275 
devices at Cleveland Clinic, 24 at Barnes–Jewish 
Hospital [only for some cases of confirmed throm-
bosis], and 269 at Duke University Medical Center). 
There were typically 12 to 24 LDH measurements 
per device (see Fig. S1 in the Supplementary Ap-
pendix, available with the full text of this article at 
NEJM.org).
End Points
The primary end point was confirmed pump 
thrombosis. Secondary end points were confirmed 
plus clinically suspected pump thrombosis, ele-
vated LDH levels, the pattern of LDH levels lead-
ing up to pump thrombosis, and outcomes after 
the management of pump thrombosis (pump re-
placement or explantation, urgent heart transplan-
tation, medical treatment, or death).
Confirmed pump thrombosis was defined as a 
thrombus found on the blood-contacting surfaces 
of the HeartMate II, its inflow cannula, or its out-
flow conduit at pump replacement, urgent trans-
plantation, or autopsy (Appendix S1 and Fig. S2 
in the Supplementary Appendix). Suspected pump 
thrombosis was defined as a clinical diagnosis 
of pump-related malfunction in which the clini-
cal or device variables suggested a thrombus on 
the blood-contacting surfaces of the pump, can-
nulae, or grafts (Appendix S1 in the Supplemen-
tary Appendix).
Management of Pump Thrombosis
Clinically suspected pump thrombosis was man-
aged by means of intravenous anticoagulation 
therapy, thrombolytic agents, and antiplatelet ther-
apy; pump replacement or explantation; or urgent 
heart transplantation. In general, centers followed 
the guidelines developed by a committee of clini-
cal experts,5 although the details of the approach 
and management strategies were specific to each 
institution and varied over time (Appendix S2 in 
the Supplementary Appendix).
Follow-up
Follow-up assessment of clinical outcomes and 
laboratory measurements occurred at intervals 
of 3 months or less after the device implantation. 
The common closing date for patients at the Cleve-
land Clinic was March 5, 2013; for those at 
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Barnes–Jewish Hospital, September 10, 2013; and 
for those at the Duke University Medical Center, 
May 16, 2013. The median follow-up at the three 
institutions was 7.8 months, 10.7 months, and 
10.4 months, respectively; the three institutions 
had 278 patient-years, 376 patient-years, and 393 
patient-years of follow-up data available for analy-
sis, respectively.
Statistical Analysis
The risk of pump thrombosis was estimated from 
the pooled multicenter data and was also estimat-
ed separately for each institution. Kap lan–Meier,6 
parametric hazard,7 and nonparametric random 
survival forest8-10 analyses (Appendix S1 in the 
Supplementary Appendix) were based on data for 
unique devices rather than data for unique pa-
tients, with time zero defined as the date of im-
plantation of each HeartMate II. Data were cen-
sored at transplantation, death, pump replacement, 
pump removal without replacement (allowed 
because of left ventricular recovery), and end of 
follow-up.
The date of implantation was incorporated into 
a parametric hazard model to identify a changing 
incidence of pump thrombosis across time. To 
corroborate parametric findings without making 
model assumptions, the data were also analyzed 
with the use of the random survival forest method 
(Appendix S1 in the Supplementary Appendix).
We hypothesized that the LDH level, which is 
indicative of hemolysis caused by thrombus for-
mation in the pump, may independently corrobo-
rate an increasing incidence of pump thrombosis. 
Therefore, each patient’s sequence of LDH mea-
surements was scanned algorithmically for LDH 
levels of more than 1000 IU per liter. Single-sample 
spikes were ignored as probable sample hemolysis, 
although the algorithm included samples immedi-
ately proximate to death, urgent transplantation, 
device replacement, or explantation. These data 
were analyzed as time-related events, exactly as 
for pump thrombosis.
For confirmed thrombosis, a landmark analy-
sis of LDH measurements was performed with 
the date of pump thrombosis set as time zero. 
The preceding 3-month longitudinal sequence of 
measurements for each device was connected by 
straight lines. A locally estimated scatterplot 
smoother (loess)11 was then fitted to the ensem-
ble of line segments.
Time zero for death after confirmed pump 
thrombosis was the date of suspected pump 
thrombosis, even if confirmation subsequently 
occurred at the time of pump replacement, ur-
gent transplantation, or autopsy. Data were cen-
sored 30 days after transplantation or pump re-
placement to capture the risks of these procedures. 
The Kaplan–Meier method was used to estimate 
time-related mortality. For reference, the com-
peting risk of death during HeartMate II support 
without pump thrombosis was generated.12
Data were analyzed with the use of SAS soft-
ware, version 9.2 (SAS Institute), and R software, 
version 3.0.2.13 For internal consistency, uncer-
tainty of estimates is expressed uniformly by 
means of 95% confidence intervals or bands simi-
lar to ±2 SE.
R esult s
Overall Incidence of Pump Thrombosis
A total of 72 confirmed pump thromboses were 
observed in 66 patients, and an additional 36 
thromboses in unique devices were suspected. 
The risk of confirmed pump thrombosis peaked 
at 1.4% per month within 1 month after implan-
tation before decreasing to a constant risk of 
0.4% per month (Fig. S3A in the Supplementary 
Appendix), with estimated occurrences of pump 
thrombosis of 4.7% during HeartMate II support 
for 6 months, 7.5% during 12 months of sup-
port, and 12.3% during 24 months of support 
(Fig. S3B in the Supplementary Appendix). This 
pattern of risk was consistent among the three 
institutions (Fig. S4 in the Supplementary Ap-
pendix). It also characterized the combined risk 
of confirmed plus suspected pump thrombosis, 
which rose to 2.0% per month within 1 month 
after implantation, then fell to 0.7% per month 
after 6 to 8 months, with estimated occurrences 
of 7.1% during HeartMate II support for 6 months, 
11.3% during 12 months of support, and 18.3% 
during 24 months of support (Fig. S5 in the Sup-
plementary Appendix).
Changing Incidence of Pump Thrombosis
The occurrence of confirmed pump thrombosis 
increased steeply after approximately March 2011, 
from 2.2% (95% confidence interval [CI], 1.5 to 
3.4) at 3 months after implantation to 8.4% 
(95% CI, 5.0 to 13.9) by January 2013 (Fig. 1, and 
Table S1 and Fig. S6 and S7 in the Supplemen-
tary Appendix). A similar pattern was observed 
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at all three institutions (Fig. 1) and for multiple 
surgeons (Fig. S8 in the Supplementary Appendix).
The median time from implantation to con-
firmed pump thrombosis decreased from 18.6 
months (95% CI, 0.5 to 52.7) before March 2011 
to 2.7 months (95% CI, 0.0 to 18.6) during and 
after March 2011. What had been a constant risk 
of confirmed pump thrombosis of 0.4% per month 
(95% CI, 0.3 to 0.5) after implantation developed 
into an early hazard that peaked at 2 months 
and then fell to a sustained 0.6% per month 
(95% CI, 0.3 to 1.2) (Fig. 2); this risk was consis-
tent across institutions (Fig. S9 in the Supple-
mentary Appendix). This pattern of change in 
the incidence of confirmed pump thrombosis 
also characterized the rate of confirmed plus 
suspected events (Table S2 and Fig. S10, S11, and 
S12 in the Supplementary Appendix).
Changing Occurrence of Elevated LDH Levels
The graph of the occurrence of LDH levels above 
1000 IU per liter within 3 months after implan-
tation was nearly superimposable on the graph 
of the occurrence of confirmed pump thrombo-
sis. The LDH data showed a parallel tendency for 
elevations to occur early after implantation be-
ginning in approximately March 2011 (Fig. 3, 
and Fig. S13 in the Supplementary Appendix).
LDH Level Presaging Pump Thrombosis
On average, the LDH level increased from 540 IU 
per liter (95% CI, 388 to 695) to 1490 IU per liter 
(95% CI, 1350 to 1600) in the 6 weeks leading 
up to confirmed pump thrombosis. This finding 
was consistent across institutions (Fig. 4, and 
Fig. S14 in the Supplementary Appendix).
Outcomes after Pump Thrombosis
There were 72 pump thromboses in 66 patients. 
A total of 11 pump thromboses were managed 
by heart transplantation in 11 patients (1 patient 
died 31 days after transplantation). A total of 21 
pump thromboses were managed by pump re-
placement in 19 patients (1 patient died >30 days 
after the pump replacement, and 1 underwent 
3 replacements). Of 40 thromboses not man-
aged by heart transplantation or pump replace-
ment, 2 thromboses in 2 patients were managed 
with pump removal, because left ventricular func-
tion had improved; 38 pump thromboses were 
managed medically in 38 patients (4 of whom 
had undergone prior device replacement), of whom 
19 died. Medical management included the aug-
mentation of anticoagulation therapy and throm-
bolytic agents, which in some cases was effective 
and stabilized the patient’s clinical course; how-
ever, some patients elected withdrawal of care 
on the basis of futility.
As compared with mortality during HeartMate 
II support among patients without confirmed 
pump thrombosis, the actuarial mortality after 
confirmed pump thrombosis at various time 
points was higher: 6.9% (95% CI, 5.4 to 8.8) 
versus 17.7% (95% CI, 9.7 to 30.1) at 30 days, 
9.7% (95% CI, 7.9 to 11.9) versus 22.4% (95% CI, 
13.0 to 35.8) at 60 days, 12.2% (95% CI, 10.1 to 
14.6) versus 27.4% (95% CI, 16.6 to 41.5) at 90 
days, and 16.8% (95% CI, 14.3 to 19.6) versus 
35.6% (95% CI, 22.9 to 50.7) at 180 days (Fig. S15A 
in the Supplementary Appendix). There was con-
siderable variation in outcomes (Fig. S15B in the 
Supplementary Appendix), depending on candi-
dacy for urgent transplantation or pump replace-
ment. Mortality at 6 months among patients 
treated with device replacement or transplanta-
tion was similar to that among patients who did 
not have device thrombosis (Fig. 5), but mortality 
was 48.2% (95% CI, 31.6 to 65.2) among patients 
with device thrombosis who were not treated with 
these methods, and this elevated mortality was 
consistent across institutions (Fig. S15C in the 
Supplementary Appendix).
Figure 1. Overall Occurrence of Confirmed Pump Thrombosis at 3 Months 
after HeartMate II Implantation.
Dashed lines represent the 95% confidence interval. There was a steep in-
crease in the occurrence of thrombosis starting in early 2011. The inset 
shows the changing occurrence of confirmed pump thrombosis according 
to study site (Cleveland Clinic [CC], Barnes–Jewish Hospital [BJH], and 
Duke University Medical Center [Duke]).
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Discussion
Approval of the HeartMate II by the Food and 
Drug Administration (FDA) has had a substantial 
impact on the care of patients with advanced 
heart failure. LVAD therapy is an important ad-
vance that is used to prolong survival and im-
prove quality of life. Refinement of all therapeutic 
innovations evolves as clinicians gain experience 
with and an understanding of device-associated 
complications and their management.
The rate of pump thrombosis with the Heart-
Mate II began increasing in March 2011 and had 
not plateaued as of mid-2013. Confirmed pump 
thrombosis occurs early and peaks 1 month after 
implantation, with a reduction in risk by 6 months. 
This rate exceeds the rates previously observed at 
our centers and reported in clinical trials.14 The 
incidence of elevated LDH levels mirrors this in-
creased rate, making it a useful clinical biomarker 
of hemolysis associated with pump thrombosis. 
Patients with pump thrombosis have increased 
morbidity and substantially increased mortality 
unless the pump is replaced or cardiac transplan-
tation is performed.
The initial analysis that revealed this sudden 
increase in the incidence of pump thrombosis 
was a clinical quality review at a single center 
(Cleveland Clinic). To confirm and strengthen 
those findings, we pooled data from two addi-
tional experienced LVAD centers and found simi-
lar results. The initial findings at the Cleveland 
Clinic were immediately sent to Thoratec and to 
the FDA. Statisticians at the Interagency Registry 
for Mechanically Assisted Circulatory Support 
(INTERMACS) conducted an analysis of 6251 
Figure 2. Occurrence and Incidence of Confirmed Pump Thrombosis Stratified According to Implantation Date.
The occurrence of confirmed pump thrombosis was stratified according to whether the date of implantation was be-
fore March 1, 2011 (gray line), or on or after that date (black line). Each symbol represents an event, and I bars indi-
cate 95% confidence intervals. The parametric estimates (solid lines) are shown with the 95% confidence intervals 
(dashed lines). The inset shows the instantaneous risk of pump thrombosis before March 1, 2011, which was con-
stant at 0.4% per month, and the risk during or after March 2011, which peaks early after implantation before falling 
to a sustained rate of 0.6% per month.
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implantations performed from April 1, 2008, to 
September 1, 2012, and found that the occur-
rence of pump thrombosis increased from 2% 
before May 2011, to 5% from May onward.15
This observation is reported on the INTERMACS 
website.15
 The INTERMACS captures data on the occur-
rence of suspected pump thrombosis on the 
basis of device replacement or death attributable 
to thrombus. Our study also included 11 of 66 
patients with device thrombosis (16.7%) who 
were rescued with urgent heart transplantation. 
Examination of the incidence of device thrombo-
sis with the use of the implantation date as a 
continuous variable and with a description of 
outcomes after therapeutic intervention pro-
vides a more complete picture of the scope and 
risks of device thrombosis. Thus, we believe the 
INTERMACS data may not accurately reflect the 
actual occurrence of pump thrombosis and its 
risks. Although the INTERMACS is a valuable 
resource, event reporting is voluntary, and defi-
nitions of adverse events are evolving. By com-
bining data from three high-volume institutions, 
we reduced the likelihood that our observations 
are an isolated single-center effect related solely 
to the management approach.
 We found that a sharp rise in LDH levels oc-
curring within the first weeks after implantation 
often preceded and heralded confirmed pump 
thrombosis. Our findings are consistent with 
those of the University of Michigan.16
 Pump function and reliability are related to 
the complex interaction between implantation 
techniques17 and anatomical constraints; patient-
level factors such as infection, bleeding, and 
adequacy of anticoagulation; pump settings; and 
device design and manufacturing.18 During the 
course of the study, implantation techniques did 
not change, and we could find no association 
between pump thrombosis and the surgeon per-
forming the implantation (Fig. S8 in the Supple-
mentary Appendix). Design changes, including 
modification of the outflow graft and bend re-
lief, inflow conduit, and software, were intro-
duced during the study period but, to our knowl-
edge, have not been directly linked to pump 
thrombosis.
 We have collectively observed, most com-
monly at explantation, that there is a deposition 
of material (fibrin and denatured protein) in 
proximity to the inflow bearing (Fig. S2 in the 
Figure 3. Elevated Lactate Dehydrogenase (LDH) Levels within 3 Months 
after HeartMate II Implantation.
 The overall estimate of the percentage of patients with LDH levels of more 
than 1000 IU per liter within 3 months after the implantation of a Heart-
Mate II is shown, without regard to diagnosis of confirmed or suspected 
pump thrombosis. The parametric estimate is shown (solid line) with the 
95% confidence interval (dashed lines). The occurrence of elevated LDH 
levels increased steadily starting in 2011, which was similar to the pattern 
observed for pump thrombosis. The inset shows changes in occurrence ac-
cording to study site.
Pa
tie
nt
s 
w
ith
 E
le
va
te
d 
LD
H
 L
ev
el
 (%
)
20
15
10
5
0
2009 20132010 2011 2012 2014
Implantation Year
25
20
15
10
5
0
2009 2010 2011 2012 2013 2014
CC
Duke
BJH
Figure 4. LDH Values before Confirmed Pump Thrombosis.
 The time of pump thrombosis (time zero) is shown at the right side of the 
graph, and LDH values up to 3 months before confirmed thrombosis are 
shown. The solid line represents the estimate of the LDH level, as generat-
ed by the locally estimated scatterplot smoother (loess), and the gray band 
represents the bootstrapped 95% confidence interval.
LD
H
 (I
U
/l
ite
r)
2000
1000
1500
500
0
−3 −2 −1 0
Months before Confirmed Pump Thrombosis
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 12, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 370;1 nejm.org January 2, 2014 39
Unexpected Abrupt Increase in LVAD Thrombosis
Supplementary Appendix), which depends on 
fluid for lubrication and flow to dissipate heat. 
Heat generation and the subsequent deposition 
of fibrin around the bearing narrows the inflow 
pathway, increasing shear stress on the red cells 
and, if the deposition is large enough, decreas-
ing the ability of the pump to unload the left 
ventricle. The bearing–fibrin deposition theory 
could explain the hemolysis that develops as 
thrombus deposition begins, escalates into 
frank pump thrombosis, and culminates in he-
modynamic compromise. We theorize that the 
changes occur in three stages: the initial stage 
is hemolysis with thrombus deposition but no 
hemodynamic compromise (thrombus forma-
tion); this may progress to hemolysis and abnor-
mal pump function (incomplete thrombosis); 
and ultimately, complete thrombosis and pump 
stoppage may occur.
Any perturbation that might reduce flow and 
heat dissipation from the bearing, or inadequate 
anticoagulation, might represent precipitating 
conditions. Known clinical factors that might 
transiently impair flow include the development 
of aortic regurgitation, arrhythmias, kinking of 
the inflow graft because of bending, and hypo-
volemia. As of this writing, the exact cause of 
the increased rate of pump thrombosis remained 
unknown.
This is a three-institution retrospective study 
with known inherent limitations. However, un-
like INTERMACS, we have extensive data on LDH 
levels and can carefully scrutinize patient records. 
The definitions of confirmed and suspected 
pump thrombosis have been revised recently by 
the INTERMACS steering committee to reflect 
elevated LDH levels as a marker of hemolysis.16 
These definitions were not available prospec-
tively for this study but were used in the indi-
vidual review of potential cases of pump throm-
bosis. This may explain differences between our 
data and INTERMACS reported events. However, 
it is possible that we underdiagnosed pump 
thrombosis before 2011, and clinically evident 
pump thrombosis does not develop in all pa-
tients with increased LDH levels. In addition, in 
the case of patients who died with the LVAD in 
situ, if an autopsy was not performed, visual 
confirmation could not take place.
Anticoagulation protocols changed during 
the course of this analysis, with some variation 
among institutions (Table S4 in the Supplemen-
tary Appendix). Nonetheless, our data suggest that 
the HeartMate II may have a more narrow toler-
ance with respect to thrombus formation than 
originally understood and may be vulnerable to 
the timing and intensity of anticoagulation.
In conclusion, we observed an increasing in-
cidence of early thrombosis with the HeartMate 
II that is associated with substantial morbidity 
and mortality. Costly device replacement or ur-
gent transplantation can be lifesaving, although 
with morbidity. Further investigation of predis-
posing patient and device factors and preventive 
and therapeutic strategies are urgently needed to 
resolve this important safety issue. We recognize 
that LVADs provide life-sustaining treatment for 
many patients with advanced heart failure. How-
ever, recommendations for LVAD therapy should 
account for this updated risk–benefit profile.
Figure 5. Mortality According to Management Strategy after Confirmed 
Pump Thrombosis.
Squares indicate deaths after heart transplantation or pump replacement, 
and diamonds indicate deaths of patients who did not undergo heart  
transplantation or pump replacement, with the horizontal axis truncated  
at 6 months. For reference, triangles indicate deaths without confirmed 
pump thrombosis during HeartMate II support from the time of implanta-
tion (gray). Symbols represent nonparametric estimates, and I bars 95% 
confidence intervals. The dashed line represents patients for whom follow-
up data were available and who remained alive.
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Unexpected Abrupt Increase in LVAD Thrombosis
Note added in proof: Pursuant to a data-sharing 
agreement with the University of Pennsylvania, 
we have completed a preliminary analysis of 150 
unique devices (placed between November 1, 
2005, and September 3, 2013) in 148 patients 
who had 15 thrombotic events (closing date, 
October 28, 2013). Similar to the findings in our 
study, the event rate has increased abruptly and 
unexpectedly, with a rate of confirmed thrombo-
sis that continues to rise.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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